Three additional participants completed the study, but their data were excluded from the analysis; two were identified as outliers, their overall performance was greater than 2 SE above the group mean, and one who produced a pattern of responding completely different from the rest of the sample.
Two additional infants took part in this experiment, but their data were excluded from the analysis because experimental sessions were discontinued due to crying and extreme side bias (100% looking to the right side of display) in the test phase.
Two additional infants took part in this experiment, but their data were excluded from the analysis because experimental sessions were discontinued due to crying and extreme side bias (100% looking to the right side of display) in the test phase described below.
Six doctors were observed but their data were excluded from the analysis (table 1).
Two further subjects participated in the fMRI study, but their data were excluded due to technical artifact.
A few children who had at least one parent who was a native English speaker took part in our project, but their data were excluded from the analyses because English was not a foreign language for them.
All HRQOL sub-study participants who completed baseline measures of all three instruments were included, but forms with missing data were excluded from the analyses.
In primary analysis, subjects with missing data were excluded, but in sensitivity analyses, patients with missing data were included with imputation of missing information [ 16].
Records were manually reviewed and any animal studies, in-vitro studies, general narrative reviews, and articles which mentioned eritoran but did not discuss trial data were excluded.
There were 17 additional Veterans who were screened into one of the above groups, but who, on inspection of their data, were excluded since they did not meet inclusion criteria for the study.
Records were manually reviewed and any animal studies, in-vitro studies, news articles, general narrative reviews, or articles which mentioned Exubera but did not discuss clinical trial data were excluded.
